ALVONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ALVOW

Alvotech

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026

$5.03+0.03 (+0.60%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 50.3
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q2 FY2026 Ended Jun 30, 2026	Aug 19, 2026	After market close	–	–	–
Q4 FY2025 Ended Dec 31, 2025	Mar 19, 2026	Before market open	$173.00M	–	–
Q2 FY2025 Ended Jun 30, 2025	Aug 13, 2025	After market close	–	–	–
Q2 FY2024 Ended Jun 30, 2024	Jul 1, 2024	Before market open	–	–	–
Q4 FY2023 Ended Dec 31, 2023	Mar 20, 2024	After market close	–	–	–
Q4 FY2022 Ended Dec 31, 2022	Mar 1, 2023	After market close	–	–	–
Q2 FY2022 Ended Jun 30, 2022	Aug 31, 2022	After market close	–	–	–

Company guidance

Outlook given with results on Mar 19, 2026, compared with the previous outlook

Measure	Period	Guidance	vs. prior
Adjusted EBITDAnon-GAAP	2026	$180.00M to $220.00M	New
total revenues	2026	$650.00M to $700.00M	New

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Alvotech filed with the SEC

Oct 14, 2026, 10:05 AM ET
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
EX-99.1 to Form 6-K
Oct 7, 2026, 10:16 AM ET
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
EX-99.1 to Form 6-K
Oct 5, 2026, 7:56 AM ET
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
EX-99.1 to Form 6-K
Aug 31, 2026, 8:00 AM ET
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations
EX-99.1 to Form 6-K
Aug 21, 2026, 10:37 AM ET
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
EX-99.1 to Form 6-K
Aug 19, 2026, 4:34 PM ET
Unaudited Condensed Consolidated Interim Financial Statements as
EX-99.1 to Form 6-K
Aug 19, 2026, 4:34 PM ET
Unless otherwise indicated or the context otherwise requires, all references to “Alvotech,” the “Company,” the “Group,” “we,” “our,” “us” or similar terms refer to Alvotech and its consolidated subsidiaries.
EX-99.2 to Form 6-K
Aug 19, 2026, 4:34 PM ET
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
EX-99.3 to Form 6-K
Jul 29, 2026, 11:00 AM ET
Alvotech announces successful closure of FDA inspection of manufacturing facility
EX-99.1 to Form 6-K
Jul 1, 2026, 8:00 AM ET
Alvotech further strengthens liquidity by securing term loan facility of $75 million
EX-99.1 to Form 6-K
Jun 18, 2026, 12:32 PM ET
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
EX-99.1 to Form 6-K
Jun 16, 2026, 7:47 PM ET
$125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
EX-99.1 to Form 6-K
Jun 16, 2026, 7:47 PM ET
Pricing of $152 Million Public Offering of
EX-99.2 to Form 6-K
Jun 8, 2026, 4:34 PM ET
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
EX-99.1 to Form 6-K
Jun 8, 2026, 4:34 PM ET
Alvotech Q1 2026 Financial Results
EX-99.2 to Form 6-K
Jun 8, 2026, 4:34 PM ET
Unaudited Condensed Consolidated Interim Financial Statements as
EX-99.3 to Form 6-K
Jun 4, 2026, 9:18 AM ET
Main Results of 2026 Annual and Extraordinary General Meeting
EX-99.1 to Form 6-K
Jun 4, 2026, 9:18 AM ET
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
EX-99.2 to Form 6-K
May 11, 2026, 8:30 AM ET
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
EX-99.1 to Form 6-K
May 4, 2026, 8:34 AM ET
Alvotech Announces a Change in its Executive Team
EX-99.1 to Form 6-K
Mar 19, 2026, 7:11 AM ET
Alvotech Q4 2025 and Full Year 2025 Financial Results
EX-99.1 to Form 6-K
Mar 19, 2026, 7:11 AM ET
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
Mar 19, 2026, 7:11 AM ET
z Full Year and Q4 2025 Earnings Presentation 19 MARCH 2026
EX-99.3 to Form 6-K
Feb 27, 2026, 7:11 AM ET
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them (HOS-2 form)
EX-99.1 to Form 6-K
Feb 27, 2026, 7:11 AM ET
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them (HOS-2 form)
EX-99.2 to Form 6-K
Feb 5, 2026, 7:00 AM ET
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
EX-99.1 to Form 6-K
Feb 2, 2026, 7:00 AM ET
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
EX-99.1 to Form 6-K
Jan 29, 2026, 7:00 AM ET
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
EX-99.1 to Form 6-K
Jan 7, 2026, 5:30 PM ET
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them (HOS-2 form)
EX-99.1 to Form 6-K
Jan 7, 2026, 5:30 PM ET
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them (HOS-2 form)
EX-99.2 to Form 6-K
Jan 7, 2026, 11:00 AM ET
and public disclosure of transactions by persons discharging managerial responsibilities and persons closely
EX-99.1 to Form 6-K
Jan 7, 2026, 11:00 AM ET
and public disclosure of transactions by persons discharging managerial responsibilities and persons closely
EX-99.2 to Form 6-K
Jan 7, 2026, 11:00 AM ET
and public disclosure of transactions by persons discharging managerial responsibilities and persons closely
EX-99.3 to Form 6-K
Jan 6, 2026, 1:07 PM ET
Alvotech announces planned CEO succession and leadership transition
EX-99.1 to Form 6-K
Jan 2, 2026, 11:16 AM ET
Alvotech Secures Term Loan Facility of USD 100 Million
EX-99.1 to Form 6-K
Dec 23, 2025, 5:29 PM ET
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
EX-99.1 to Form 6-K
Dec 19, 2025, 9:57 AM ET
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
EX-99.1 to Form 6-K
Dec 17, 2025, 8:37 AM ET
Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering
EX-99.1 to Form 6-K
Nov 24, 2025, 8:00 AM ET
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area
EX-99.1 to Form 6-K
Nov 20, 2025, 7:45 AM ET
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
EX-99.1 to Form 6-K

Where these numbers come from

Parsed from the XBRL in Alvotech's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ALVO.

Revenue growth19.7% · median 34.5%

Gross margin59.8% · median 81.8%

Operating margin13.3% · median -5.2%

Company	Revenue	Growth
TECH	$1.22B	-0.4%
BCRX	$940.61M	+68.7%
ALVO	$586.32M	+19.7%
IMCR	$430.78M	+21.0%
MGTX	$397.50M	+948.3%
IOVA	$324.97M	+34.5%

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 1,000
Auditor: Deloitte ehf.
SEC CIK: 1898416

Advertisement
300 × 250